Model Medicines Named Among Top AI Drug Development Startups to Watch in 2025
Press Coverage
Patrick ONeill
The feature highlights our GALILEO™ platform's impressive track record of discovering 192 compounds across 26 targets, including our leading pan-antiviral candidate, MDL-001.
Patrick ONeill
Head of Partnerships and Investor Relations
We are honored to be recognized as one of the "5 Innovative AI Drug Development Startups to Watch in 2025" for our groundbreaking work in AI-driven drug development. The feature highlights our GALILEO™ platform's impressive track record of discovering 192 compounds across 26 targets, including our leading pan-antiviral candidate, MDL-001.
The article, which spotlights companies revolutionizing the pharmaceutical industry through artificial intelligence, recognizes Model Medicines' unique approach to modeling chemistry and human biology for accelerated drug development. Our inclusion among these innovative companies reflects our commitment to using AI technology to create life-changing medications more efficiently and effectively.
Read the full article to learn more about how Model Medicines and other cutting-edge startups are transforming the future of drug development through artificial intelligence.
Note: The original article was published in GreyB's Life Sciences and Pharmaceuticals sector review of emerging AI drug development companies.
